novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Why weight-loss drug shows promise for heart disease F.D.A. Approves New Obesity Drug

Semaglutide deep-dive Semaglutide is sold under three brand names, all manufactured by Novo Nordisk: Ozempic -- weekly injection, FDA-approved for type 2 diabetes (doses 0.25 mg, 0.5 mg, 1 mg, 2 mg) Wegovy -- weekly injection, FDA-approved for chronic weight management in 2021 (doses up to 2.4 mg) [3] Rybelsus -- daily oral tablet, approved for type 2 diabetes For weight loss specifically, Wegovy is the on-label choice

The SURMOUNT-1 clinical trial showed an average of 16% body weight reduction at the 5mg dose over 72 weeks

Sergey Terushkin or a licensed provider and sent directly to a partner pharmacy Dr

This way, your medication can be safely monitored and administered

This means patients might see better results with injectable semaglutide (like Wegovy or Ozempic) for both blood sugar control and weight loss